Navigation Links
Techne Corporation Releases Unaudited Third Quarter and Nine Month Fiscal Year 2012 Results
Date:5/1/2012

MINNEAPOLIS, May 1, 2012 /PRNewswire/ -- Techne Corporation's (NASDAQ: TECH) financial results for the third quarter and nine months ended March 31, 2012 include the following highlights:

Third quarter earnings were $31.8 million or $0.86 per diluted share.  Adjusted earnings for the quarter were $33.1 million or $0.90 per diluted share, an increase of 5.9% from the same prior-year period. Adjusted earnings and earnings per share exclude intangible asset amortization and costs recognized upon the sale of inventory that was written-up to fair value as part of the acquisitions of Boston Biochem, Inc. and Tocris Holdings Limited completed in the quarter ended June 30, 2011.  Adjusted earnings and earnings per diluted share also exclude the impact of impairment charges on certain equity investments and the reversal of deferred tax asset valuation allowances.

Earnings for the nine-month period ended March 31, 2012 were $85.1 million or $2.30 per diluted share.  Adjusted earnings for the nine-month period ended March 31, 2012 were $91.1 million or $2.46 per diluted share, an increase of 7.9% from the same prior-year period.

Net sales as reported grew 9.6% to $83.6 million for the quarter ended March 31, 2012. Organic sales grew 1.8% in the quarter compared to the same prior-year period.  Organic sales exclude sales from acquisitions and the changes in foreign currency rates.

Net sales as reported grew 11.3% to $236 million for the nine months ended March 31, 2012.  Organic sales grew 2.3% in the nine-month period compared to the same prior-year period.

A stronger U.S. dollar as compared to foreign currencies reduced sales by $587,000 in the quarter ended March 31, 2012 from the comparable prior-year quarter.  A weaker U.S. dollar as compared to foreign currencies improved sales by $1.5 million in the nine-month period ended March 31, 2012 from the comparable prior-year period.

The Biotechnology segment includes sales made through R&D Systems' Biotechnology Division, R&D Systems Europe, Tocris, R&D Systems China, BiosPacific and Boston Biochem.  Biotechnology segment net sales were $78.2 million for the quarter ended March 31, 2012, an increase of 9.9% from $71.1 million for the quarter ended March 31, 2011.  Biotechnology net sales were $220 million for the nine-month period ended March 31, 2012, an increase of 11.7% from $197 million for the nine-month period ended March 31, 2011.  Biotechnology sales growth was 1.5% and 2.0% for the quarter and nine month periods ended March 31, 2012, respectively, if sales from the acquisitions and foreign currency effect are excluded.

Organic sales growth for the Biotechnology segment from the same prior-year periods were:Period Ended March 31, 2012Quarter

Nine MonthsU.S. industrial, pharmaceutical  and biotechnology

5.6%

5.7%U.S. academic

(5.4%)

(4.9%)Europe

(0.4%)

(0.6%)China

19.9%

22.4%Pacific Rim

7.8%

6.5%Hematology net sales for the quarter and nine-month period ended March 31, 2012 were $5.4 million and $15.6 million, increases of 5.6% and 6.2%, respectively, from the comparable prior-year periods.

The gross margin percentage declined to 75.8% in the quarter ended March 31, 2012 from 79.1% in the comparable prior-year quarter and to 75.0% in the nine-month period ended March 31, 2012 from 78.0% in the comparable prior-year period, due to costs recognized upon the sale of inventory that was written-up to fair value as part of the acquisitions and the amortization of intangible assets.  Gross margins were 79.0% and 79.2% for the quarters ended March 31, 2012 and 2011, respectively, and 78.5% and 78.2% for the nine-month periods ended March 31, 2012 and 2011, respectively, if such costs were excluded in all periods.

Selling, general and administrative expenses for the quarter and nine-month period ended March 31, 2012 increased $604,000 and $6.0 million, respectively, from the quarter and nine-month periods ended March 31, 2011. The acquired businesses added $795,000 and $3.2 million of selling, general and administrative expenses, excluding intangible asset amortization, in the quarter and nine-month periods ended March 31, 2012, respectively.  Intangible amortization included in selling, general and administrative expenses increased $456,000 and $1.4 million in the quarter and nine-month period ended March 31, 2012, respectively, from the same prior-year periods. Selling, general and administrative expense for the quarter and nine-month period ended March 31, 2011 included $211,000 of professional fees related to the acquisitions.Other expense for the quarter and nine-month period ended March 31, 2012 included $3.3 million of impairment losses on investments in unconsolidated entities.  These losses were the result of Nephromics, LLC signing an agreement to sell substantially all of its assets and ACTGen, Inc. suffering substantial operating losses and encountering funding difficulties. 

Other non-operating expenses include foreign exchange transaction gains of $164,000 and losses of $465,000, respectively, for the quarter and nine-month period ended March 31, 2012, compared to foreign exchange transaction gains of $249,000 and $667,000 for the quarter and nine-month period ended March 31, 2011, respectively.

The effective tax rate for the quarter and nine-month period ended March 31, 2012 was 26.5% and 30.0%, respectively, as compared to 31.6% and 31.2% for the same prior-year periods. Income taxes for the quarter and nine-month period ended March 31, 2012 were positively impacted by $3.0 million due to the reversal of a valuation allowance on deferred tax assets related to the excess tax basis in the Company's investments in unconsolidated entities.  The tax rate for the remainder of fiscal 2012 is expected to be 31% to 33%.In September 2011, the Company entered into a $10.0 million loan agreement with ChemoCentryx, Inc. (CCXI).  The loan agreement contained a number of conversion features contingent upon CCXI obtaining future debt or equity financing.  The agreement also included a $5.0 million commitment by the Company to participate in a private placement in the event of a successful public offering of CCXI shares.  With CCXI's completion of its initial public offering during the quarter ended March 31, 2012, the loan plus accrued interest was converted to common shares and the Company purchased the additional $5 million of common equity as required by its previous commitment. At March 31, 2012, the Company's investment in CCXI was included in short-term available-for-sale investments at its fair market value of $66.5 million. The Company's unrealized gain of $37.0 million, net of deferred tax liability of $13.2 million, was included in accumulated other comprehensive income at March 31, 2012.  The Company's investment in CCXI was $14.3 million at June 30, 2011 and was included in other non-current assets.

The Company repurchased 45,983 and 309,010 shares of its common stock during the quarter and nine months ended March 31, 2012, respectively, for approximately $3.1 million and $21.3 million.  Approximately $29.3 million remains available at March 31, 2012 for the repurchase and retirement of shares under the currently open authorization.

Forward Looking Statements:
Our press releases may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act. Such statements, including the expected effective tax rate, involve risks and uncertainties that may affect the actual results of operations. The following important factors, among others, have affected and, in the future, could affect the Company's actual results: the integration of the acquired companies, the introduction and acceptance of new biotechnology and hematology products, the levels and particular directions of research by the Company's customers, the impact of the growing number of producers of biotechnology research products and related price competition, general economic conditions, the retention of hematology OEM and proficiency survey business, the impact of currency exchange rate fluctuations, and the costs and results of research and product development efforts of the Company and of companies in which the Company has invested or with which it has formed strategic relationships.

For additional information concerning such factors, see the section titled "Risk Factors" in the Company's annual report on Form 10-K and quarterly reports on Form 10-Q as filed with the Securities and Exchange Commission.  We undertake no obligation to update or revise any forward-looking statements we make in our press releases due to new information or future events. Investors are cautioned not to place undue emphasis on these statements.

Use of Adjusted Financial Measures:
The adjusted financial measures used in this press release quantify the impact the following events had on reported net sales, gross margin percentages, selling, general and administrative expenses, net earnings and earnings per share for the quarter and nine-month period ended March 31, 2012 as compared to the reported amounts for the same periods ended March 31, 2011:

  • fluctuations in exchange rates used to convert transactions in foreign currencies (primarily the Euro, British pound sterling and Chinese yuan) to U.S. dollars;
  • the acquisitions of Boston Biochem on April 1, 2011 and Tocris on April 28, 2011, including the impact of amortizing intangible assets and the recognition of costs upon the sale of inventory written-up to fair  value;
  • impairment losses related to the Company's investments in unconsolidated entities; and
  • the reversal of valuation allowances on deferred tax assets related to the excess tax basis in the Company's unconsolidated entities. 
  • These adjusted financial measures are not prepared in accordance with generally accepted accounting principles (GAAP) and may be different from adjusted financial measures used by other companies.  Adjusted financial measures should not be considered as a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP.  We view these adjusted financial measures to be helpful in assessing the Company's ongoing operating results.  In addition, these adjusted financial measures facilitate our internal comparisons to historical operating results and comparisons to competitors' operating results.  We include these adjusted financial measures in our earnings announcement because we believe they are useful to investors in allowing for greater transparency related to supplemental information we use in our financial and operational analysis. Investors are encouraged to review the reconciliations of adjusted financial measures used in this press release to their most directly comparable GAAP financial measures as provided with the financial statements attached to this press release.

    Techne Corporation has two operating subsidiaries:  Research and Diagnostic Systems, Inc. (R&D Systems) of Minneapolis, Minnesota and R&D Systems Europe, Ltd. (R&D Europe) of Abingdon, England.  R&D Systems is a specialty manufacturer of biological products.  R&D Systems has three operating subsidiaries:  BiosPacific, Inc. (BiosPacific), located in Emeryville, California, Boston Biochem, Inc., located in Cambridge, Massachusetts and R&D Systems China Co. Ltd., (R&D China), located in Shanghai, China.  BiosPacific is a worldwide supplier of biologics to manufacturers of in vitro diagnostic systems and immunodiagnostic kits. Boston Biochem is a leading developer and manufacturer of ubiquitin-related research products. R&D China and R&D Europe distribute biotechnology products.  R&D Europe has two subsidiaries: Tocris Holdings Ltd (Tocris) of Bristol, England and R&D Systems GmbH, a German sales operation.  Tocris is a leading supplier of reagents for non-clinical life science research.

    TECHNE CORPORATION

    CONSOLIDATED STATEMENTS OF EARNINGS

    (In thousands, except per share data)

    (Unaudited)

     QUARTER ENDEDNINE MONTHS ENDED3/31/12

    3/31/11

    3/31/12

    3/31/11Net sales

    $83,621

    $76,271

    $235,879

    $211,924Cost of sales

    20,238

    15,941

    58,939

    46,618Gross margin

    63,383

    60,330

    176,940

    165,306Operating expenses:Selling, general and administrative

    9,899

    9,295

    31,323

    25,335Research and development

    7,122

    6,297

    20,626

    19,519Total operating expenses

    17,021

    15,592

    51,949

    44,854Operating income

    46,362

    44,738

    124,991

    120,452Other income (expense):Interest income

    470

    1,067

    1,996

    2,934Impairment losses on investments in unconsolidated entities

    (3,254)

    0

    (3,254)

    0Other non-operating expense, net

    (373)

    (421)

    (2,155)

    (1,376)Total other (expense) income

    (3,157)

    646

    (3,413)

    1,558Earnings before income taxes

    43,205

    45,384

    121,578

    122,010Income taxes

    11,449

    14,320

    36,488

    38,039Net earnings

    $31,756

    $31,064

    $85,090

    $83,971Earnings per share:Basic

    $   0.86

    $   0.84

    $
    2.30

    $   2.26Diluted

    $   0.86

    $   0.84

    $
    2.30

    $   2.26Weighted average common shares outstanding:  Basic

    36,864

    37,119

    36,975

    37,084  Diluted

    36,930

    37,194

    37,043

    37,153TECHNE CORPORATION

    CONSOLIDATED BALANCE SHEETS

    (In thousands)

    (Unaudited)ASSETS

    3/31/12

    6/30/11Cash and equivalents

    $95,280

    $ 77,613Short-term available-for-sale investments

    124,325

    63,200Trade accounts receivable

    39,114

    35,914Inventory

    40,497

    44,906Other current assets

    7,056

    8,784  Current assets

    306,272

    230,417Available-for-sale investments

    145,129

    131,988Property and equipment, net

    94,614

    95,398Goodwill and intangible assets, net

    134,876

    138,915Other non-current assets

    3,143

    20,952  Total assets

    $684,034

    $617,670LIABILITIES AND STOCKHOLDERS' EQUITYAccounts payable and accrued expenses

    $  14,620

    $  12,679Payable for pending available-for-sale investment purchases

    7,360

    0Income taxes – deferred and current

    8,741

    5,509  Current liabilities

    30,721

    18,188Deferred taxes

    8,816

    13,360Stockholders' equity

    644,497

    586,122  Total liabilities and stockholders' equity

    $684,034

    $617,670TECHNE CORPORATION

    RECONCILIATION of ORGANIC SALES

    (In thousands)

    (Unaudited)QUARTER ENDEDNINE MONTHS ENDED3/31/12

    3/31/11

    3/31/12

    3/31/11Net sales

    $83,621

    $76,271

    $235,879

    $211,924Organic sales adjustments:Acquisitions

    (6,600)

    0

    (17,655)

    0Impact of foreign currency fluctuations

    587

    0

    (1,529)

    0Organic sales 

    $77,608

    $76,271

    $216,695

    $211,924Organic sales growth

    1.8%2.3%TECHNE CORPORATION

    RECONCILIATION of NET EARNINGS and EARNINGS per SHARE

    (In thousands, except per share data)

    (Unaudited)QUARTER ENDEDNINE MONTHS ENDED3/31/12

    3/31/11

    3/31/12

    3/31/11Net earnings

    $31,756

    $31,064

    $85,090

    $83,971Identified adjustments:Costs recognized upon sale of acquired inventory

    1,955

    0

    5,870

    0Amortization of intangibles

    1,268

    170

    3,821

    511Acquisition related professional fees

    0

    211

    0

    211Impairment losses on investments

    3,254

    0

    3,254

    0Tax impact of above adjustments

    (2,069)

    (137)

    (3,883)

    (263)Tax impact of reversal of valuation allowance

    (3,016)

    0

    (3,016)

    01,392

    244

    6,046

    459Net earnings – adjusted for identified  items

    $33,148

    $31,308

    $91,136

    $84,430Adjusted growth

    5.9%7.9%Earnings per share – Diluted – adjusted

    $0.90

    $   0.84

    $2.46

    $
    2.27TECHNE CORPORATION

    RECONCILIATION of GROSS MARGIN PERCENTAGES

    (Unaudited)QUARTER ENDEDNINE MONTHS ENDED3/31/12

    3/31/11

    3/31/12

    3/31/11Gross margin percentage

    75.8%

    79.1%

    75.0%

    78.0%Identified adjustments:Costs recognized upon sale of acquired inventory

    2.3%

    0.0%

    2.5%

    0.0%Amortization of intangibles

    0.9%

    0.1%

    1.0%

    0.2%Gross margin percentage – adjusted

    79.0%

    79.2%

    78.5%

    78.2%TECHNE CORPORATION

    RECONCILIATION of SELLING, GENERAL and ADMINISTRATIVE EXPENSES

    (In thousands)

    (Unaudited)QUARTER ENDEDNINE MONTHS ENDED3/31/12

    3/31/11

    3/31/12

    3/31/11Selling, general and administrative expenses

    $9,899

    $9,295

    $31,323

    $25,335Identified selling, general and administrative expense adjustments:Acquired companies' expense, excluding intangible amortization

    (795)

    0

    (3,160)

    0Amortization of intangibles

    (518)

    (62)

    (1,558)

    (185)Acquisition related professional fees

    0

    (211)

    0

    (211)Selling, general and administrative expenses – adjusted

    $8,586

    $9,022

    $26,605

    $24,939TECHNE CORPORATION

    RECONCILIATION of INTANGIBLE AMORTIZATION

    (In thousands)

    (Unaudited)QUARTER ENDEDNINE MONTHS ENDED3/31/12

    3/31/11

    3/31/12

    3/31/11Amortization of intangible assets included in:Cost of goods sold

    $   750

    $108

    $2,263

    $326Selling, general and administrative expenses

    518

    62

    1,558

    185Total amortization of intangible assets

    $1,268

    $170

    $3,821

    $511


    '/>"/>
    SOURCE Techne Corporation
    Copyright©2010 PR Newswire.
    All rights reserved


    Related medicine technology :

    1. Techne Corporation Declares Dividend
    2. Techne Corporation Releases Unaudited First Quarter Fiscal Year 2012 Financial Results
    3. Techne Corporation Releases Unaudited Fourth Quarter and Fiscal Year 2011 Results
    4. Technest Holdings, Inc. to Acquire AccelPath, LLC; Issue Contingent Value Rights to Common Stockholders; and Issue Shares of Its Series E 5% Convertible Preferred Stock
    5. Techne Corporation Declares Dividend
    6. Techne Corporation Declares Dividend
    7. ShangPharma Corporation Files 2011 Annual Report on Form 20-F
    8. Luminex Corporation Reports First Quarter 2012 Results
    9. Haemonetics Signs Definitive Agreement to Acquire Pall Corporations Blood Collection, Filtration and Processing Product Lines For $551 Million
    10. Richard Wolf Medical Instruments Corporation: 40 Years of Innovation
    11. CVS Caremark Corporation to Hold First Quarter 2012 Conference Call
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:6/26/2016)... , June 27, 2016  VMS Rehab Systems, ... Board will take whatever measures required to build a ... stock which is currently listed on the OTC Markets-pink ... Company Chairman and CEO, "We are seeing an anomaly ... to understand, not only by the Company, but shareholders ...
    (Date:6/24/2016)... 24, 2016  Collagen Matrix, Inc., ("Collagen Matrix") ... manufacturing of collagen and mineral based medical devices ... Bill Messer has joined the company ... leverage the growing portfolio of oral surgery, neurosurgery, ... Bill joins the Collagen Matrix executive team as ...
    (Date:6/24/2016)... 24, 2016 ... the addition of the " Global Markets for ... This report focuses on ... updated review, including its applications in various applications. The ... which includes three main industries: pharmaceutical and biotechnology, food ...
    Breaking Medicine Technology:
    (Date:6/27/2016)... KS (PRWEB) , ... June 27, 2016 , ... TopConsumerReviews.com ... retailers of Eyeglasses . , Millions of individuals in the United States and ... have become a way to both correct vision and make a fashion statement. Even ...
    (Date:6/26/2016)... , ... June 26, 2016 , ... Brent Kasmer, a legally blind and certified personal ... personalized through a fitness app. The fitness app plans to fix the two major problems ... offer a one size fits all type program , They don’t eliminate all ...
    (Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX ... Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms over ... Cut Pro X . Simply select a ProHand generator and drag it above media ...
    (Date:6/25/2016)... Montreal, Canada (PRWEB) , ... June 25, 2016 , ... ... the pursuit of success. In terms of the latter, setting the bar too high ... low, risk more than just slow progress toward their goal. , Research from ...
    (Date:6/24/2016)... Texas (PRWEB) , ... June 24, 2016 , ... ... International Conference and Scientific Sessions in Dallas that it will receive two significant ... of the grants came as PHA marked its 25th anniversary by recognizing patients, ...
    Breaking Medicine News(10 mins):